4.8 Review

American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline

期刊

CA-A CANCER JOURNAL FOR CLINICIANS
卷 66, 期 1, 页码 44-73

出版社

WILEY
DOI: 10.3322/caac.21319

关键词

breast cancer; survivorship; clinical care; follow-up; guideline; primary care; quality of life; survivorship care plan; long-term effects; late effects; care coordination

类别

资金

  1. Centers for Disease Control and Prevention [5U55DP003054]
  2. American Cancer Society/Centers for Disease Control
  3. Prevention for the National Cancer Survivorship Resource Center project
  4. Prevention for the National Cancer Survivorship Resource Center project as well as a grant from Genentech
  5. a consulting fee from Pfizer
  6. Amgen
  7. Takeda Oncology outside the submitted work
  8. Boehringer Ingelheim
  9. GTx Inc, as well as GlaxoSmithKline
  10. Celgene
  11. Elekta
  12. Accuray
  13. Morphormics
  14. Sun Nuclear
  15. United Health International outside the submitted work
  16. Breast Cancer Research Foundation for investigator-initiated research
  17. Susan G. Komen for the Cure as a Komen Scholar
  18. NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO [U55DP003054] Funding Source: NIH RePORTER

向作者/读者索取更多资源

The purpose of the American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline is to provide recommendations to assist primary care and other clinicians in the care of female adult survivors of breast cancer. A systematic review of the literature was conducted using PubMed through April 2015. A multidisciplinary expert workgroup with expertise in primary care, gynecology, surgical oncology, medical oncology, radiation oncology, and nursing was formed and tasked with drafting the Breast Cancer Survivorship Care Guideline. A total of 1073 articles met inclusion criteria; and, after full text review, 237 were included as the evidence base. Patients should undergo regular surveillance for breast cancer recurrence, including evaluation with a cancer-related history and physical examination, and should be screened for new primary breast cancer. Data do not support performing routine laboratory tests or imaging tests in asymptomatic patients to evaluate for breast cancer recurrence. Primary care clinicians should counsel patients about the importance of maintaining a healthy lifestyle, monitor for post-treatment symptoms that can adversely affect quality of life, and monitor for adherence to endocrine therapy. Recommendations provided in this guideline are based on current evidence in the literature and expert consensus opinion. Most of the evidence is not sufficient to warrant a strong evidence-based recommendation. Recommendations on surveillance for breast cancer recurrence, screening for second primary cancers, assessment and management of physical and psychosocial long-term and late effects of breast cancer and its treatment, health promotion, and care coordination/practice implications are made. (C) 2015 American Cancer Society.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据